Vencur10 mg/vial

Vencur is an FDA-approved, established treatment indicated as an adjunct to general anesthesia for the following uses:

• Facilitation of endotracheal intubation: Vencur is used to produce the skeletal muscle relaxation required for smooth and rapid endotracheal tube placement during induction of general anesthesia.
• Skeletal muscle relaxation during surgery: Vencur provides sustained muscle relaxation to facilitate surgical procedures under general anesthesia.
• Facilitation of mechanical ventilation: Vencur is used in the intensive care setting as an adjunct to provide muscle relaxation in mechanically ventilated patients when required.

Vencur has no sedative, analgesic, or anesthetic properties of its own and must always be given together with adequate general anesthesia or sedation and analgesia.

Each vial of Vecuronium Bromide for injection contains vecuronium bromide as a sterile, lyophilized (freeze-dried) powder, commonly available in strengths such as 4 mg and 10 mg per vial, for reconstitution with a compatible diluent prior to intravenous use. It contains no preservative unless specifically reconstituted with bacteriostatic diluent.

Vencur is a synthetic, intermediate-acting, non-depolarizing (competitive) skeletal muscle relaxant belonging to the aminosteroid class of neuromuscular blocking agents. It is supplied as a sterile lyophilized powder that is reconstituted with a compatible diluent immediately before intravenous administration.

Vencur is used exclusively in hospital and operating-room/intensive-care settings by clinicians trained in anesthesia and airway management, as it produces complete skeletal muscle paralysis, including of the muscles of respiration.

Vencur belongs to the therapeutic class of non-depolarizing (competitive) neuromuscular blocking agents, specifically the aminosteroid (steroidal) subclass, which also includes agents such as pancuronium and rocuronium. It is classified as an intermediate-duration muscle relaxant used as an anesthesia adjunct.

Vecuronium Bromide is a non-depolarizing neuromuscular blocking agent that acts by competitively binding to nicotinic acetylcholine receptors on the motor end-plate of the neuromuscular junction, thereby blocking the action of acetylcholine and preventing depolarization of the muscle membrane. This antagonism is reversible and can be overcome by increasing the local concentration of acetylcholine, for example with acetylcholinesterase inhibitors such as neostigmine.

Following intravenous administration of Vecuronium Bromide, onset of effect typically occurs within 2.5-3 minutes at intubating doses, with clinically effective duration of approximately 25-40 minutes; the drug is metabolized to a small extent in the liver and is eliminated primarily via biliary excretion, with a lesser amount cleared renally.

Vencur is for intravenous administration only, given as a bolus injection or as a continuous infusion using a calibrated infusion device. It must never be given by any other route.

• Reconstitute the lyophilized powder with a compatible diluent immediately before use (see Reconstitution).
• Administer only after the patient is unconscious (or adequately sedated) and has adequate analgesia, since Vencur has no sedative or analgesic effect.
• Continuous cardiovascular and neuromuscular (twitch response) monitoring is required throughout administration.
• Do not mix Vencur in the same syringe or administer through the same needle as alkaline solutions (e.g., barbiturate/thiopental solutions), as this may cause precipitation.

Vencur has several clinically significant drug interactions that can alter the intensity or duration of neuromuscular blockade:

• Volatile inhalation anesthetics (e.g., isoflurane, enflurane, halothane, sevoflurane): potentiate and prolong the neuromuscular blocking effect of Vencur; dose reduction is often required.
• Succinylcholine: when given before Vencur, can enhance and prolong its effect; administration of Vencur should be delayed until early spontaneous recovery from succinylcholine begins.
• Aminoglycoside and other antibiotics (e.g., aminoglycosides, tetracyclines, polymyxin B, clindamycin, lincomycin): may potentiate neuromuscular blockade through effects at the neuromuscular junction, increasing the risk of prolonged paralysis.
• Magnesium salts: enhance neuromuscular blockade by reducing acetylcholine release, which is particularly relevant in obstetric patients treated for pre-eclampsia/eclampsia.
• Other non-depolarizing neuromuscular blockers: may produce additive or synergistic effects when used together; concurrent use is not well studied and requires caution.
• Electrolyte and acid-base disturbances (e.g., hypokalemia, hypocalcemia, respiratory acidosis): can enhance blockade, while alkalosis may antagonize it.
• Quinidine: may cause recurrent neuromuscular blockade (recurarization) when given during the recovery period.

Anesthesia providers should review all concurrent medications before and during use of Vencur.

The most significant risk associated with Vencur is an extension of its expected pharmacological action beyond the period needed, resulting in prolonged skeletal muscle weakness or paralysis, including of the respiratory muscles, which can lead to respiratory insufficiency or apnea if not properly managed with ventilatory support.

Other reported side effects include:

• Skin flushing
• Hypotension
• Tachycardia or, less commonly, bradycardia
• Bronchospasm
• Rash or urticaria

Rare but serious: severe anaphylactic or anaphylactoid reactions, which can be life-threatening, have been reported with Vencur and other neuromuscular blocking agents. Prolonged use in the intensive care unit has been associated with prolonged muscle weakness, myopathy, and muscle atrophy that may take an extended period to resolve.

Pregnancy: Data on the use of Vencur in human pregnancy are limited. Vencur has been used during cesarean section at doses up to 0.1 mg/kg, with reports of minimal placental transfer and no adverse neonatal effects noted in those reports; however, formal reproductive safety studies are lacking. Vencur should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use should always be under the direct supervision of an anesthesiologist and only after consulting a physician.

Lactation: It is not known whether Vencur is excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised when Vencur is administered to a breastfeeding woman; a physician should be consulted regarding breastfeeding after anesthesia involving Vencur.

Vencur should be administered only by, or under the direct supervision of, anesthesiologists or clinicians experienced in the use of neuromuscular blocking agents and airway management, with facilities for immediate tracheal intubation, artificial/mechanical ventilation, and oxygen administration readily available at all times.

• No sedative or analgesic effect: Vencur causes complete paralysis but has no effect on consciousness or pain perception; it must always be used together with adequate general anesthesia or sedation and analgesia.
• Respiratory paralysis: Vencur paralyzes the respiratory muscles; ventilatory support must be provided until adequate spontaneous respiration is restored.
• Hepatic or renal impairment: may prolong the duration of action of Vencur, since it is partly cleared by hepatic and renal pathways; dose adjustment and close monitoring are advised.
• Neuromuscular disorders (e.g., myasthenia gravis, Eaton-Lambert syndrome): patients may show markedly increased sensitivity to Vencur; use a peripheral nerve stimulator, consider a test dose, and reduce the dose as needed.
• Electrolyte imbalances: conditions such as hypokalemia or hypermagnesemia can alter sensitivity to Vencur and should be corrected where possible before use.
• Hypothermia: prolongs the duration of neuromuscular blockade produced by Vencur.
• Obesity: dosing should take into account ideal versus actual body weight to avoid overdosing.
• Confirmation of recovery: adequate recovery from neuromuscular blockade must be confirmed, ideally with objective neuromuscular monitoring, before extubation or discontinuation of ventilatory support; reversal agents (e.g., neostigmine or other acetylcholinesterase inhibitors) may be used according to institutional anesthesia protocol.
• Anaphylaxis: severe, potentially fatal anaphylactic reactions have been reported; immediate treatment facilities must be available.

Overdose or excessive effect of Vencur presents as prolonged skeletal muscle paralysis, which may include prolonged apnea and inability to breathe independently. This is a medical emergency requiring immediate medical attention.

Management should be carried out only by trained anesthesia/critical-care personnel and generally includes maintaining a patent airway, providing mechanical ventilation and adequate sedation/analgesia until spontaneous respiration and muscle strength return, monitoring neuromuscular function with a peripheral nerve stimulator, and administering an appropriate acetylcholinesterase inhibitor reversal agent (such as neostigmine, together with an antimuscarinic agent) once spontaneous recovery has begun, per institutional protocol. Do not attempt to manage suspected overdose outside of a monitored clinical setting; contact emergency services or poison control immediately if excessive dosing is suspected.

Store unreconstituted Vencur vials at controlled room temperature (approximately 20-25°C/68-77°F), protected from light. Once reconstituted, use according to the diluent-specific storage and expiry instructions provided with the product, and discard any unused reconstituted solution as directed. Keep out of reach of children and use only under professional medical supervision in a hospital setting.

Elderly: Vencur can generally be used in elderly patients at standard doses, though onset may be somewhat delayed and recovery slightly prolonged; individualized monitoring is recommended.

Pediatric patients: see Pediatric Uses for detailed age-based dosing guidance.

Obese patients: dosing of Vencur should be based on ideal body weight rather than actual body weight to avoid excessive or prolonged neuromuscular blockade.

Hepatic or renal impairment: may result in prolonged action of Vencur; see Dosage and Administration and Precautions and Warnings.

Neuromuscular disease (e.g., myasthenia gravis): increased sensitivity to Vencur requires reduced doses and close monitoring; see Precautions and Warnings.

Vencur is used for the duration of a single surgical procedure, anesthesia episode, or period of mechanical ventilation, as determined by the anesthesiologist or intensive-care physician. It is not intended for outpatient or self-administered use, and dosing is repeated or infused only as long as continued neuromuscular blockade is clinically required, guided by neuromuscular monitoring.

Vencur is supplied as a sterile lyophilized powder that must be reconstituted with a compatible diluent immediately before intravenous use.

• Compatible diluents include 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Water for Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, and Lactated Ringer's Injection.
• When reconstituted with bacteriostatic water for injection (containing benzyl alcohol), the solution should generally be used within 5 days of preparation; bacteriostatic diluents should not be used in neonates.
• When reconstituted without a preservative, the solution should be used promptly and any unused portion discarded, per institutional protocol and the specific product's prescribing information.
• Gently swirl to dissolve; do not shake vigorously. Inspect visually for particulate matter or discoloration before use, and discard if present.
• Do not mix with alkaline solutions in the same syringe or IV line.

Vecuronium Bromide belongs to the following drug classification:

• Neuromuscular blocking agent
• Non-depolarizing (competitive) muscle relaxant
• Aminosteroid (steroidal) class
• Intermediate-duration anesthesia adjunct

Vecuronium Bromide acts by competitively blocking acetylcholine at nicotinic receptors on the motor end-plate of skeletal muscle, preventing depolarization and subsequent muscle contraction. This non-depolarizing block can be antagonized (reversed) by acetylcholinesterase inhibitors, which increase the local concentration of acetylcholine available to compete with Vecuronium Bromide at the receptor.

C

Use of Vencur in pediatric patients requires careful, age-specific consideration:

• Neonates and infants under 7 weeks of age: safety and effectiveness of Vencur have not been established in this age group; use only with extreme caution, individualized dosing, and continuous neuromuscular monitoring.
• Infants 7 weeks to 1 year: generally show greater sensitivity to Vencur on a mg/kg basis and a longer time to spontaneous recovery compared with older children and adults; doses should be individualized.
• Children 1-10 years: may require a slightly higher initial dose and more frequent maintenance dosing than adults.
• Children 10-16 years: dosing requirements are generally similar to adult dosing.

In all pediatric age groups, Vencur must be administered only by clinicians experienced in pediatric anesthesia, with continuous cardiorespiratory monitoring and immediate ventilatory support available.